Cocrystal Pharma, Inc. announced that the first subjects have been dosed in its Phase 1b norovirus challenge study evaluating CDI-988 as a preventive and treatment for norovirus infections at Emory University School of Medicine. This milestone advances the first oral antiviral drug candidate targeting norovirus 3CL protease amid a significant unmet medical need.
Key takeaways
First subjects dosed in Phase 1b norovirus challenge study (NCT07198139) on March 9, 2026
Study evaluates CDI-988 for prevention and treatment of GII.2 (Snow Mountain Virus) norovirus infections
Randomized, double-blind, placebo-controlled trial enrolling up to 40 healthy subjects ages 18–49
Primary endpoint: efficacy in reducing clinical symptoms vs placebo; secondary: viral shedding, disease severity, safety, PK
CDI-988 previously safe in Phase 1 up to 1200 mg dose; FDA Study May Proceed Letter in September 2025
Study at Emory University School of Medicine; first direct-acting antiviral trial for norovirus